Last update 01 Nov 2024

OnQuality Pharmaceuticals (USA) LLC1

Private Company|
2019|
United States

Overview

Tags

Other Diseases
Skin and Musculoskeletal Diseases
Immune System Diseases
Small molecule drug
Chemical drugs

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Immune System Diseases3
Neoplasms1
Top 5 Drug TypeCount
Small molecule drug6
Unknown1
Chemical drugs1
Top 5 TargetCount
JAK(Janus kinase)2
sGC(Soluble guanylate cyclase)1

Related

9
Drugs associated with OnQuality Pharmaceuticals (USA) LLC1
OQL-011
Target
sGC
Mechanism
sGC stimulants [+1]
Active Org.
OnQuality Pharmaceuticals (USA) LLC1 [+3]
Originator Org.
OnQuality Pharmaceuticals Ltd.OnQuality Pharmaceuticals Ltd.Startup
Active Indication
Allergic skin reaction [+3]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
OQL-025
Target
JAK
Mechanism
JAK inhibitors
Active Org.
OnQuality Pharmaceuticals Ltd.OnQuality Pharmaceuticals Ltd.Startup [+1]
Originator Org.
OnQuality Pharmaceuticals Ltd.OnQuality Pharmaceuticals Ltd.Startup
Active Indication
Acneiform Eruptions [+1]
Inactive Indication-
Drug Highest PhaseIND Approval
First Approval Ctry. / Loc.-
First Approval Date-
OQL-036
Target-
Mechanism-
Active Org.
OnQuality Pharmaceuticals Ltd.OnQuality Pharmaceuticals Ltd.Startup [+1]
Originator Org.
OnQuality Pharmaceuticals Ltd.OnQuality Pharmaceuticals Ltd.Startup
Active Indication
Hand-Foot Syndrome
Inactive Indication-
Drug Highest PhaseIND Approval
First Approval Ctry. / Loc.-
First Approval Date-
3
Clinical Trials associated with OnQuality Pharmaceuticals (USA) LLC1
CTR20221809 / Active, not recruitingPhase 2
一项在接受VEGFR抑制剂后导致手足皮肤反应的癌症患者中评价OQL011安全性和有效性的II期研究
[Translation] A Phase II Study Evaluating the Safety and Efficacy of OQL011 in Cancer Patients with Hand-Foot Skin Reactions after VEGFR Inhibitors
CTRI/2023/01/048670 / Active, not recruitingPhase 2
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
NCT04088318 / Active, not recruitingPhase 2
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
100 Clinical Results associated with OnQuality Pharmaceuticals (USA) LLC1
Login to view more data
0 Patents (Medical) associated with OnQuality Pharmaceuticals (USA) LLC1
Login to view more data
100 Deals associated with OnQuality Pharmaceuticals (USA) LLC1
Login to view more data
100 Translational Medicine associated with OnQuality Pharmaceuticals (USA) LLC1
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
3
1
Preclinical
IND Application
3
1
IND Approval
Phase 2 Clinical
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
OQL-011
 ( sGC )		Neoplasms
More
Phase 2
OQL-051
 ( CDK4 x CDK6 )		Diarrhea
More
IND Approval
OQL-012
Allergic skin reaction
More
IND Application
OQL-025
 ( JAK )		Exanthema
More
IND Application
OQL-036
Hand-Foot Syndrome
More
IND Application
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free